The good, the bad and the ugly of the new treatments for hepatitis C virus

Autores: Silva Vidal Karen V, Méndez Sánchez Nahum


Article commented: Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60: 37-45. Comment: Approximately 185 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver diseases each year. Until 2011, the standard of care for patients with HCV genotype1 (GT1) was pegylated interferon (PEG-IFN) plus ribavirin, which in clinical trials have shown a moderate efficacy unfortunately with many adverse effects.

Palabras clave:

2014-08-28   |   278 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.5. Septiembre-Octubre 2014 Pags. 574-575 Ann Hepatol 2014; 13(5)